A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01302587|
Recruitment Status : Completed
First Posted : February 24, 2011
Last Update Posted : June 22, 2012
|Condition or disease||Intervention/treatment|
|Asthma Chronic Obstructive Pulmonary Disease (COPD) Emphysema Chronic Bronchitis||Drug: Albuterol|
|Study Type :||Observational|
|Actual Enrollment :||306 participants|
|Official Title:||A Prospective, Open Label, Assessment of [an Albuterol] Hydrofluoroalkane (HFA) Metered Dose Inhaler MDI Integrated Dose Counter|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||June 2011|
All participants in this study will receive an albuterol MDI inhaler.
Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
- The number of times the counter advanced but the inhaler did not actuate [ Time Frame: Days 1 through 46 ]MDI actuates but the counter display does not advance.
- The number of times the inhaler actuated but the counter did not advance. [ Time Frame: Days 1 through 46 ]Counter advances but the MDI does not actuate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01302587
|Study Director:||Clinical Project Leader||Teva Respiratory R&D|